Abbott 2004 Global Citizenship Report - Abbott Laboratories

More documents

Recommendations

Info

We Advance Leading-EdgeScience and TechnologiesDistinguished Research Fellow HingSham is the primary inventor ofKaletra, Abbott’s second-generationprotease inhibitor for the treatmentof HIV infection, and co-inventor ofNorvir, our first protease inhibitordeveloped to treat the disease.11
Leading-Edge Science and TechnologiesWe advance leading-edge science and technologies that hold the potentialfor significant improvements to health and to the practice of health care.Abbott has been recognized as having one of the best newproductpipelines in the health care industry. Top-tierscientific capability is critical to our success and will remainat the center of our strategy for the future. We haveincreased our research and development investmentsignificantly over the past five years, and, as a result, wehave become a leader in monoclonal antibody research.And, through our varied medical products businesses, weare developing new technologies across a broad range oftherapeutic areas and markets.We focus on breakthrough medical science that changesthe way patients are treated and, as a result, changes theirlives. Humira, our rheumatoid arthritis medicine, is one suchadvance. It leads the way in what we expect to be asuccession of biological products based on our leadingmonoclonal antibody technology. Our experimental cancercompound, Xinlay, is the first drug in an entirely new classwith breakthrough potential for patients.In medical products, our Freestyle Navigator glucosemonitoring system was recognized by TIME magazine as oneof the most promising new medical technologies on thehorizon. And in molecular diagnostics, a field that did noteven exist only a few years ago, we now offer productsthat are changing lives. For example, our PathVysion testuses an advanced technology called FISH (fluorescence insitu hybridization) to identify theprecise type of cancer a patient isfighting and, consequently, the besttreatment therapy.The discovery and development ofnew medicines and medicaltechnologies is a risky, costly andtime-consuming process, and wouldnot be possible without a strongsystem that respects intellectualproperty. The patent systemeffectively balances the societalgoals of encouraging innovation andproviding access to its benefits. Wemanage our patents in the long-terminterests of patients and ourshareholders. We are committed tousing the patent system responsibly.We respect the intellectual propertyrights of others and expect others todo the same.Sabine Lieder, of Abbott Germany inLudwigshafen, evaluates a potentialcompound.1.6Total Research andDevelopment Spending(dollars in billions)1.624 1.6971.492 1.4751.21.2460.80.40.02000 2001 2002 2003 200412
Page 1: Living Our Values2004 Global Citize
Page 4 and 5: A Promise for LifeTurning Science i
Page 6 and 7: About AbbottAbbott is headquartered
Page 8 and 9: Citizenshipat AbbottTom Wistar of t
Page 10 and 11: Citizenship at AbbottWe improved ou
Page 12 and 13: Citizenship at AbbottTaking Action
Page 16 and 17: Leading-Edge Science and Technologi
Page 19 and 20: Developing New GlucoseMonitoring Te
Page 21 and 22: We Value Our DiversityWe value our
Page 23 and 24: We Value Our DiversitySupplier Dive
Page 25 and 26: Exceptional PerformanceWe focus on
Page 27 and 28: Exceptional PerformanceWaste Reduct
Page 29 and 30: Exceptional PerformanceNonhazardous
Page 31 and 32: Leadership in EHSA Conversation Wit
Page 33 and 34: Exceptional PerformanceA Respectful
Page 35 and 36: We Strive to Earn the Trust of Thos
Page 37 and 38: Globalization of the Office of Ethi
Page 39 and 40: Promoting an Ethical CultureA Conve
Page 41 and 42: Critical Issue:Counterfeit Products
Page 43 and 44: We Sustain SuccessWe sustain succes
Page 45 and 46: Picturing HopeIn 2004, the Abbott F
Page 47 and 48: Contributing NutritionalExpertise i
Page 49 and 50: We Sustain SuccessEmployee Involvem
Page 51 and 52: Index of Key TermsA Access to medic

Abbott 2004 Global Citizenship Report - Abbott Laboratories

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?